Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.57 - $1.28 $23,156 - $52,000
40,625 Added 42.17%
136,955 $112,000
Q4 2022

Feb 13, 2023

BUY
$1.13 - $4.15 $6,231 - $22,887
5,515 Added 6.07%
96,330 $241,000
Q2 2022

Aug 12, 2022

BUY
$1.19 - $3.04 $7,906 - $20,197
6,644 Added 7.89%
90,815 $114,000
Q1 2022

May 13, 2022

SELL
$1.98 - $2.98 $1,168 - $1,758
-590 Reduced 0.7%
84,171 $244,000
Q4 2021

Feb 11, 2022

BUY
$1.88 - $2.9 $38,985 - $60,137
20,737 Added 32.39%
84,761 $194,000
Q3 2021

Nov 12, 2021

BUY
$2.3 - $2.86 $14,754 - $18,346
6,415 Added 11.14%
64,024 $163,000
Q2 2021

Aug 13, 2021

BUY
$2.52 - $3.18 $40,599 - $51,232
16,111 Added 38.82%
57,609 $164,000
Q1 2021

May 12, 2021

SELL
$2.47 - $4.39 $570 - $1,014
-231 Reduced 0.55%
41,498 $129,000
Q2 2020

Aug 13, 2020

SELL
$1.53 - $4.53 $30,653 - $90,758
-20,035 Reduced 32.44%
41,729 $143,000
Q1 2020

May 14, 2020

SELL
$1.18 - $5.86 $16,507 - $81,975
-13,989 Reduced 18.47%
61,764 $122,000
Q4 2019

Feb 13, 2020

BUY
$2.85 - $4.2 $3,613 - $5,325
1,268 Added 1.7%
75,753 $303,000
Q3 2019

Nov 12, 2019

BUY
$1.95 - $3.93 $18,016 - $36,309
9,239 Added 14.16%
74,485 $237,000
Q2 2019

Aug 14, 2019

BUY
$3.45 - $26.86 $101,809 - $792,638
29,510 Added 82.58%
65,246 $254,000
Q4 2018

Feb 13, 2019

BUY
$16.55 - $30.22 $71,115 - $129,855
4,297 Added 13.67%
35,736 $719,000
Q3 2018

Nov 13, 2018

BUY
$18.0 - $32.83 $565,902 - $1.03 Million
31,439 New
31,439 $969,000

Others Institutions Holding ACER

# of Institutions
1
Shares Held
365
Call Options Held
0
Put Options Held
0

About Acer Therapeutics Inc.


  • Ticker ACER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,100,000
  • Description
  • Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...
More about ACER
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.